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ABSTRACT
Introduction: Adequate persistence to antidia-
betic treatment is highly important to achieve
proper glycemic control. In this study we eval-
uate the persistence to treatment with dipep-
tidyl peptidase-4 inhibitors, sodium-glucose co-
transporter-2 inhibitors, and glucagon-like
peptide-1 receptor agonists in a nationwide
cohort of patients with type 2 diabetes.
Methods: Using a central database in Hungary,
we analyzed the persistence to the treatment
with dipeptidyl peptidase-4 inhibitors
(n = 59,900), sodium-glucose co-transporter-2
inhibitors (n = 26,052), and glucagon-like pep-
tide-1 receptor agonists (n = 17,332) at treat-
ment intensification between 2014 and 2016.
We also compared the persistence of dipeptidyl
peptidase-4 inhibitors (n = 9163) and sodium-
glucose co-transporter-2 inhibitors (n = 1257) in
initial therapy to that of metformin
(n = 79,305) or sulfonylureas (n = 29,057). The
rates of persistence to treatment and risk of
non-persistence are reported.
Results: The persistence rates of dipeptidyl
peptidase-4 inhibitors, sodium-glucose co-
transporter-2 inhibitors, and glucagon-like
peptide-1 receptor agonists at treatment inten-
sification were 69.6%, 67.8%, and 66.3% at year
1 which decreased to 57.3%, 56.8%, and 52.1%
by year 2, respectively. The risk of non-persis-
tence was higher by 6.6% (95% CI 3.6–9.6) for
sodium-glucose co-transporter-2 inhibitors and
by 8.3% (95% CI 5.0–11.5) for glucagon-like
peptide-1 receptor agonists as compared to
dipeptidyl peptidase-4 inhibitors. Novel oral
antidiabetic drugs in fixed versus free add-on
combinations with metformin had higher per-
sistence. The persistence to treatment with
novel oral antidiabetic drugs in initial therapy
was better (dipeptidyl peptidase-4 inhibitors,
59.6% and 47.6%; sodium-glucose co-trans-
porter-2 inhibitors, 61.9% and 47.0%) than that
of initial monotherapy with metformin (47.0%
and 39.1%) or sulfonylureas (52.4% and 41.8%)
at years 1 and 2, respectively.
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Conclusion: Analysis of persistence of treat-
ment with novel glucose-lowering medications
revealed differences between drug classes,
favoring dipeptidyl peptidase-4 inhibitors vs.
sodium-glucose co-transporter-2 inhibitors and
glucagon-like peptide-1 receptor agonists. Per-
sistence data of novel antihyperglycemic agents
may be useful for guiding the decision at initi-
ation of antidiabetic treatment.
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summary available for this article.
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PLAIN LANGUAGE SUMMARY
Although type 2 diabetes is a very frequent
metabolic disease in adulthood and among the
elderly, its manifestation is often symptomless.
Patients with type 2 diabetes should be treated
with glucose-lowering pills or injectable drugs
(i.e., insulin or other agents) to achieve nor-
malization of elevated blood glucose values.
This treatment with medications alongside
lifestyle modification may prevent or at least
decrease the risk of late complications due to
permanently high blood glucose values which
may affect the eyes, kidneys, nerves, and car-
diovascular system. Failure of adequate treat-
ment may ultimately lead to increased
morbidity (blindness, chronic kidney disease,
amputation) and mortality. We care for our
diabetic patients regularly for years because
medications cannot definitively reverse the
metabolic abnormalities. Persistence to treat-
ment (duration of prescribed medication use) is
of great importance in the long run as it may
affect the outcome of the disease.
In the last couple of years, new and innova-
tive glucose-lowering pills became available. In
addition, when glucose levels remain too high
there are new options for applying medication
by a small needle at the abdominal wall or
thighs. We investigated three new glucose-
lowering drugs called dipeptidyl peptidase-4
inhibitors (DPP-4 inhibitors), sodium-glucose
co-transporter-2 inhibitors (SGLT-2 inhibitors)
(both are pills), and glucagon-like peptide-1
receptor agonists (GLP-1-RAs, an
injectable medication) to assess whether
patients follow the physicians’ instructions and
use these medications accordingly. We used the
database of the National Institute of Health
Insurance Fund Management in Hungary. We
found that patients were more likely to con-
tinue treatment with DPP-4 inhibitors as com-
pared to SGLT-2 inhibitors or GLP-1 RAs. We
suggest that it is reasonable for clinicians to
consider—among others—persistence data
when prescribing novel antidiabetic drugs to
patients with type 2 diabetes mellitus.
INTRODUCTION
The burden of type 2 diabetes mellitus has been
widely recognized. The recent prevalence rate
and the estimated increase in incidence of type
2 diabetes create a severe global health problem
[1]. The research activity in development of new
antidiabetic drugs for treating type 2 diabetes
was very successful in the last decade. New
classes of drugs (DPP-4 inhibitors, GLP-1-RAs,
and SGLT-2 inhibitors) became available and
broadened the armamentarium of antidiabetic
drugs for treating people with type 2 diabetes
[2].
Persistence to treatment is a key element
associated with the effectiveness of pharmaco-
logical therapies in patients with diabetes mel-
litus. The antihyperglycemic agents work in
different ways to lower blood glucose levels.
Besides patients’ characteristics, the mode of
administration (oral, injectable), glycemic
effect, and potential risks (hypoglycemia,
weight gain, cardiovascular safety profile, side
effects) of antihyperglycemic agents should be
considered when deciding the pharmacological
treatment for diabetes [3, 4]. The success of
antidiabetic treatment may be influenced by
several factors and persistence to treatment
should be considered important in this regard
[5]. Although persistence to a particular antidi-
abetic drug depends on the patient’s age,
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gender, ethnicity, social conditions, and
comorbidities [6], specific characteristics of the
treatment such as complexity of dosing regi-
men, safety, tolerability, and cost may also play
an important role [7]. Even therapeutic inertia
in the antihyperglycemic treatment can be a
concern [8].
While several studies were earlier performed
to assess the persistence to treatment with tra-
ditional oral antidiabetic drugs [metformin
(MET) and sulfonylureas (SUs)] [9, 10], such
data with novel agents are limited [11–20] and
lacking from the Central-Eastern European
countries. Therefore, the aim of our study was
to evaluate the persistence of prescribed treat-
ment with novel antidiabetic drugs (DPP-4
inhibitors, SGLT-2 inhibitors, and GLP-1-RAs)
in a nationwide cohort of people with type 2
diabetes in Hungary.
METHODS
In this study we used the database of the
National Institute of Health Insurance Fund
Management (Hungary). All data were anon-
ymized at data extraction, and we used non-
identifiable data at further analyses. In this
central database, all antidiabetic drugs pre-
scribed with reimbursement and dispensed in
pharmacies nationwide are regularly registered.
Actually, a near 3-year-long period from January
1, 2014 was investigated. The persistence of
novel antidiabetic drugs was analyzed in two
treatment options:
1. First, we focused on treatment intensifica-
tion with novel antidiabetic drugs on failure
with first treatment option. Accordingly, we
captured the new antihyperglycemic agents
either in monotherapy (switched from
another former drug) or in add-on combi-
nations with different former drugs and the
persistence to the treatment with DPP-4
inhibitors (n = 59,900), SGLT-2 inhibitors
(n = 26,052), and GLP-1-RAs (n = 17,332)
was assessed. In a subanalysis, the persis-
tence of fixed and free add-on combinations
of DPP-4 inhibitors with MET (n = 21,167
and n = 1986, respectively) and those of
SGLT-2 inhibitors with MET (n = 4286 and
n = 2603, respectively) were separately
investigated.
2. Secondly, we focused on the treatment
initiation and the persistence of DPP-4
inhibitors (n = 9163) and SGLT-2 inhibitors
(n = 1257) was assessed and compared to
that of initial monotherapy with MET
(n = 79,305) or SUs (n = 29,057).
In Hungary, five DPP-4 inhibitors (sitaglip-
tin, vildagliptin, saxagliptin, linagliptin, alo-
gliptin) and two SGLT-2 inhibitors
(dapagliflozin, empagliflozin) and their fixed
combinations with MET are available. As for
GLP-1-RAs, exenatide twice daily, exenatide
once weekly, liraglutide, and lixisenatide can be
prescribed. All these drugs are reimbursed at
70%. As for MET, different preparations exist
and five SUs (glibenclamide, gliclazide, gliq-
uidone, glimepiride, glipizide) are available in
Hungary, all of which are reimbursed at 55%.
People starting with the particular antidia-
betic therapy from January 1, 2014 were enrol-
led in this study. The year of 2013 was used as
reference year in order to detect only the real
starting therapy in 2014. For each person, dis-
pensing of the prescribed drugs was followed
until October 31, 2016, followed by a permissi-
ble gap of 180 days (grace period) until 30 April,
2017.
The persistence curves were obtained by
shifting the individual treatments initiated
during the entire study period into the zero
point. The numerical value of persistence was
determined as a percentage of the initial popu-
lation that remained on therapy in each drug
classes [21]. Treatment was considered persis-
tent if the medicine was dispensed throughout
the study period irrespective of other antidia-
betic drugs, if any. Consequently, treatment
was classified non-persistent if a patient started
the antidiabetic therapy and then later—in-
cluding the grace period—did not continue the
treatment with the respective antidiabetic drug.
It was determined in advance for how many
days the defined dosage forms of the medica-
tion would last for a person. On the basis of
these results, we calculated for how long the
dispensed quantities would be enough. A grace
period of 180 days was applied according to the
International Society for Pharmacoeconomics
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and Outcomes Research (ISPOR) guidelines
often used in international literature [22]. The
therapy was considered continuous if the indi-
vidual still had medication 180 days before the
end of the study period. The treatment was
considered non-persistent if the last dispensed
amount of medication had been used up, based
on the earlier dosing, and within a further
180 days no repeated dispensing occurred. In
other words, persistence was defined as the
duration of time from initiation to discontinu-
ation of the particular therapy and a permissible
gap of 180 days (grace period) was allowed
between the last day on therapy and the next
refill of prescription. Analyses with shorter grace
periods (120, 90, and 60 days) in our cohort
revealed an approximately 3–4% decrease in
persistence rate at year 1 and 2 but we decided
to remain at the less strict 180-day grace period.
Death cases were censored, meaning that they
were registered but not counted for persistence
analysis.
The numerical value of persistence of the
actual drug therapy (the proportion of persis-
tent people in the initial cohort) was deter-
mined at two predefined time points (year 1 and
year 2, i.e., 12 months and 24 months after the
initiation of the medication, respectively). In
addition, Kaplan–Meier curves were generated
with age- and gender-corrected values of length-
of-therapy data and Cox proportional hazard
analysis was used for evaluating hazard ratio
with 95% confidence interval (HR; 95% CI) of
non-persistence.
At treatment intensification we also assessed
the persistence to treatment in patients with
different age by decades. For statistical analysis
we formed three age groups (B 50,
51–70, C 71 years) and used the Tukey contrast
method for making a comparison.
In this research we used non-identifiable
data obtained from the database of the National
Institute of Health Insurance Fund Manage-
ment, Hungary. This article does not contain
any studies with human participants or animals
performed by any of the authors. Therefore,
informed consent was not required. A study
license number was needed and provided (S04/
168/2017) by the National Institute of Health
Insurance Fund Management, Hungary.
RESULTS
The persistence rates of DPP-4 inhibitors, SGLT-
2 inhibitors, and GLP-1-RAs at treatment
intensification were 69.6%, 67.8%, and 66.3%
at year 1 which decreased to 57.3%, 56.8%, and
52.1% by year 2, respectively (Fig. 1). Regarding
the entire period (24 months), the risk of non-
persistence was significantly higher for SGLT-2
inhibitors (HR 1.066, 95% CI 1.036–1.096;
p\0.0001) and for GLP-1-RAs (HR 1.083, 95%
CI 1.050–1.116; p\0.0001) as compared to
DPP-4 inhibitors.
At treatment intensification with DPP-4
inhibitors, the proportion of persistent patients
was lower in patients aged B 50 vs. C 51 years
(Table 1). Regarding the entire period
(24 months), the risk of non-persistence was
significantly higher in patients aged B 50 vs.
51–70 years (HR 1.259, CI 1.203–1.318;
p\0.0001) but no difference in risk was found
in patients aged C 71 vs. B 50 years (HR 1.013,
CI 0.971–1.056; p = 0.734). In case of SGLT-2
inhibitors, the persistence was the best in
patients aged between 41 and 60 years (Table 1).
Regarding the entire period (24 months), there
was no difference in risk of non-persistence
between patients aged B 50 vs. 51–70 years (HR
0.996, CI 0.927–1.070; p = 0.992) but the risk
was higher in patients aged C 71 vs. 51–70 years
(HR 1.415, CI 1.290–1.551; p\0.0001). In
Fig. 1 Persistence to novel antidiabetic drugs [dipeptidyl
peptidase-4 inhibitors (DPP-4 inhibitors), sodium glucose
co-transporter-2 inhibitors (SGLT-2 inhibitors), glucagon-
like peptide-1 receptor agonists (GLP-1-RAs)] used in
treatment intensiﬁcation on failure with the initial drug
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patients treated with GLP-1-RAs, the persistence
was the best at age between 51 and 70 years
(Table 1). Regarding the entire period
(24 months), the risk of non-persistence was
significantly higher in patients aged B 50 vs.
51–70 years (HR 1.138, CI 1.065–1.217;
p\0.0001) and in patients with aged C 71 vs.
51–70 years (HR 1.353, CI 1.197–1.529;
p\0.0001).
Treatment with DPP-4 inhibitors or SGLT-2
inhibitors in fixed versus free add-on combina-
tions with MET had higher persistence rates
(Table 2). Regarding the entire period
(24 months for DPP-4 inhibitors and 12 months
for SGLT-2 inhibitors), the risk of non-persis-
tence was considerably lower for fixed versus
free add-on MET combinations with DPP-4
inhibitors (HR 0.549, 95% CI 0.513–0.587;
p\0.0001) or with SGLT-2 inhibitors (HR
0.550, 95% CI 0.498–0.607; p\0.0001).
The persistence rates of treatment with novel
oral antidiabetic drugs (DPP-4 inhibitors, SGLT-
2 inhibitors) in initial therapy were much better
at year 1 and year 2 than those of MET or SUs
(Table 2). Regarding the entire period
(24 months), the risk of non-persistence was
significantly lower for DPP-4 inhibitors versus
MET (HR 0.771, 95% CI 0.746–0.797;
p\0.0001) or SUs (HR 0.812, 95% CI
0.782–0.842; p\0.0001). Similarly, the risk of
non-persistence was significantly lower for
SGLT-2 inhibitors versus MET (HR 0.706, 95%
CI 0.639–0.779; p\0.0001) or SUs (HR 0.706,
95% CI 0.638–0.781; p\0.0001).
DISCUSSION
Our study demonstrates that at treatment
intensification with novel antidiabetic drugs,
DPP-4 inhibitors have the highest persistence
rate followed by SGLT-2 inhibitors and GLP-1-
RAs. Novel oral antidiabetic drugs in fixed
combinations with MET have significantly
higher persistence than that of free add-on
combinations. The persistence to treatment
with novel oral antidiabetic agents (DPP-4
inhibitors, SGLT-2 inhibitors) in initial therapy
is much better than that with MET or SUs.
We used a nationwide database to determine
persistence to treatment with different antihy-
perglycemic drug classes. It is widely accepted
that pharmacy claims databases are a reliable
source of data based on prescription refills.
Using such database, one can perform an accu-
rate analysis of persistence to a treatment in
chronic diseases such as diabetes [23].
In our analysis we investigated a near 3-year-
long period from 2014 to 2017. Although DPP-4
inhibitors became available 8–10 years ago,
Table 1 Persistence to treatment (proportion of persistent people according to age decades) with novel antihyperglycemic
agents at treatment intensiﬁcation in patients with type 2 diabetes
Age
(years)
DPP-4 inhibitors SGLT-2 inhibitors GLP-1-RAs
Patients
(n)
At year 1
(%)
At year 2
(%)
Patients
(n)
At year 1
(%)
At year 2
(%)
Patients
(n)
At year 1
(%)
At year 2
(%)
B 30 291 50.9 35.4 115 54.5 149 43.2 33.4
31–40 1858 59.2 40.5 1054 66.3 1154 62.2 42.8
41–50 6764 68.2 51.8 4279 70.0 59.0 3626 67.1 48.7
51–60 17,910 69.8 56.6 10,256 70.2 60.3 6776 68.0 55.4
61–70 20,100 71.3 60.0 8281 66.3 55.0 4580 66.8 53.7
C 71 12,977 69.5 59.6 2067 58.0 44.9 1047 57.8 49.6
Total 59,900 69.6 57.3 26,052 67.8 56.8 17,332 66.3 52.1
DPP-4 dipeptidyl peptidase-4, SGLT-2 sodium-glucose co-transporter-2, GLP-1-RAs glucagon-like peptide-1 receptor
agonists
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GLP-1-RAs reached the market later and SGLT-2
inhibitors could be prescribed only in the last
couple of years. As our original aim was to per-
form a comparative analysis in the same period,
the timeframe of availability of SGLT-2 inhibi-
tors was taken into account.
In our study we used the term persistence.
Although there is no clear distinction in some
publications between the terms persistence and
adherence, and sometimes they are used inter-
changeably in the literature, we maintain the
term persistence—the duration of medication
use—as an important indicator of adherence
[24, 25].
We evaluated the rates of persistence to the
treatment with particular antihyperglycemic
drug classes at prespecified time points but we
also assessed the hazard ratios of non-persis-
tence by using persistence curves. Although
persistence (or non-persistence) data can easily
be followed in our study, we acknowledge that
another method (i.e., evaluating proportion of
days covered) is still in use in the literature [23].
Although persistence to diabetes medication
is of great importance, non-persistence is com-
mon and varies according to classes of drugs
[26]. Former retrospective database analyses
from the USA and Germany documented that
DPP-4 inhibitors have better persistence than
traditional antidiabetic drugs such as SUs or
thiazolidinediones [11, 12]. Similar results were
found in another study which used a database
from the UK [13]. In 2015, the persistence of
oral antidiabetic drugs proved to be suboptimal
Table 2 Persistence to treatment (proportion of persistent people) with novel antihyperglycemic agents in patients with
type 2 diabetes
Persistence analysis People
(n)
Age (years;
x – SD)
Women
(%)
Persistence
At year 1
(%)
At year 2
(%)
Drugs in monotherapy or combinations after failing with ﬁrst antihyperglycemic agents
DPP-4 inhibitors 59,900 63.6 ± 11.0 49.9 69.6 57.3
SGLT-2 inhibitors 26,052 60.4 ± 9.5 48.3 67.8 56.8
GLP-1-RAs 17,332 57.9 ± 10.0 47.3 66.3 52.1
Drugs with ﬁxed versus add-on free combinations
DPP-4 inhibitors ? MET ﬁxed combination 21,167 62.7 ± 10.8 47.3 65.4 52.1
DPP-4 inhibitors ? MET add-on free
combination
1986 65.3 ± 11.1 54.6 44.6 30.9
SGLT-2 inhibitors ? MET ﬁxed
combination
4286 59.6 ± 9.5 47.5 75.6 –
SGLT-2 inhibitors ? MET add-on free
combination
2603 59.5 ± 9.4 49.5 55.7 –
Drugs in initial treatment
DPP inhibitors 9163 59.6 ± 12.9 49.5 59.6 47.6
SGLT-2 inhibitors 1257 56.9 ± 11.1 47.6 61.9 47.0
MET 79,305 60.3 ± 12.8 52.5 47.0 39.1
SUs 29,057 66.4 ± 12.4 56.0 52.4 41.8
DPP-4 dipeptidyl peptidase-4, SGLT-2 sodium-glucose co-transporter-2, GLP-1-RAs glucagon-like peptide-1 receptor
agonists, MET metformin, SUs sulfonylureas
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in a meta-analysis [14]. A study from the USA
recently documented a better persistence with
the SGLT-2 inhibitor canagliflozin compared to
dapagliflozin, GLP-1-RAs, or DPP-4 inhibitors
[15]. Another study also from the USA reported
on better persistence of initial SGLT-2 inhibitors
than newly initiated treatment with SUs [16]. In
a recent large comparative study from the UK,
persistence to older and newer oral antidiabetic
drugs was analyzed and the results suggested
that medication class was the major influencing
factor in medication persistence [17]. Among
the GLP-1-RAs, dulaglutide had better persis-
tence data than that of once-weekly exenatide
or liraglutide [18]. To the best of our knowledge,
our study is the first report from Central-Eastern
Europe demonstrating the persistence rates of
all novel antidiabetic drug classes either at
treatment intensification or at initial treatment.
The data from our region add to the current
body of knowledge on persistence of novel
antidiabetic drugs.
Regarding our results, two recent real-world
studies from the USA are of particular interest.
Using the same large database (US Centricity
Electronic Medical Records), the authors repor-
ted on—among others—the discontinuation
rate of DPP-4 inhibitors, GLP-1-RAs, and SGLT-2
inhibitors in patients with type 2 diabetes.
When these drugs were used as initial treat-
ment, the discontinuation rates at year 1 were
17%, 20%, and 25% resulting in persistence of
83%, 80%, and 75%, respectively. When these
drugs were used as second treatment, the dis-
continuation rates at year 1 were 18%, 21%, and
25% resulting in persistence of 82%, 79% and
75%, respectively. Although the numbers differ,
the ranking order of persistence of these novel
antidiabetic drugs is very close to what we
found in our study either at treatment intensi-
fication or at initial treatment [19]. In another
publication the authors reported on the sus-
tainability of desirable glycemic control over
2 years with major second-line antidiabetic
therapies. They found that patients with sec-
ond-line incretin-based drugs (DPP-4 inhibitors,
GLP-1-RAs) had higher probability of achieving
and sustaining acceptable glycemic control
compared with those treated with SUs or insulin
[20]. Unfortunately, we could not perform such
analysis as no laboratory parameters were
recorded in our database. Additionally, our data
suggest that age of patients may have some
influence on persistence (with DPP-4 inhibitors,
persistence was higher in patients aged C 51
vs. B 50 years; with SGLT-2 inhibitors, the
worst persistence data was observed in patients
aged C 71 years; while with GLP-1-RAs, the best
persistence rate was observed in patients aged
51–70 years).
It was earlier documented that management
of type 2 diabetes using fixed-dose combina-
tions provides a compliance benefit relative to
free add-on combinations [27, 28]. In this
regard our study should be considered confir-
matory with novel oral antidiabetic drugs with
MET combinations.
Our results have to be interpreted within the
context of their limitations. In our study no
specific data were available about important
covariates such as severity of the disease,
comorbidities, glycemic control, HbA1c values,
BMI, renal function, socioeconomic status, or
incidence of side effects (especially hypo-
glycemic event rates) of ongoing antidiabetic
treatment. While we acknowledge the impor-
tance of these cofounders, we feel that our
results are meaningful for characterizing the
persistence of treatment with novel antidiabetic
drugs in our region. Nevertheless, the general-
izability of our results is limited because the
healthcare system and accesses to different
treatment options are country-specific. In this
regard it is noteworthy that our study was based
a nationwide register which should be consid-
ered as a strength of the investigation. It is also
of note that although the prices of novel drugs
in different antidiabetic classes differ, all have
the same (70%) reimbursement in our country.
CONCLUSION
The analysis of persistence of treatment with
novel glucose-lowering medications revealed
significant differences between drug classes,
favoring DPP-4 inhibitors vs. SGLT-2 inhibitors
and GLP-1-RAs, and between free and fixed-dose
MET combinations, favoring the latter. These
data should be useful in clinical practice and
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might be considered as a factor that help to
guide the decision about antidiabetic treatment.
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